Barclays PLC Innate Pharma Sa Transaction History
Barclays PLC
- $327 Billion
- Q2 2024
A detailed history of Barclays PLC transactions in Innate Pharma Sa stock. As of the latest transaction made, Barclays PLC holds 412 shares of IPHA stock, worth $943. This represents 0.0% of its overall portfolio holdings.
Number of Shares
412
Previous 412
-0.0%
Holding current value
$943
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding IPHA
# of Institutions
9Shares Held
242KCall Options Held
0Put Options Held
0-
Optiver Holding B.V. Amsterdam, P787.4KShares$200,0360.0% of portfolio
-
Exchange Traded Concepts, LLC86.2KShares$197,4820.0% of portfolio
-
Morgan Stanley New York, NY43.5KShares$99,6690.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il23.5KShares$53,8760.0% of portfolio
-
Ubs Group Ag297Shares$6800.0% of portfolio
About Innate Pharma SA
- Ticker IPHA
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,893,000
- Market Cap $183M
- Description
- Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...